Additionally, patients undergoing AML therapy with targeted agents such as FLT3 or IDH1/IDH2 inhibitors should have the specific targeted gene as an NGS-MRD marker, in combination with other markers that are present in the sample [6]. Here, FLT3 is linked to acute myeloid leukemia.